149 related articles for article (PubMed ID: 33860432)
1. Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review.
Zaina A; Grober Y; Abid A; Arad E; Golden E; Badarny S
Endocrine; 2021 Jul; 73(1):65-70. PubMed ID: 33860432
[TBL] [Abstract][Full Text] [Related]
2. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
3. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
Bamgboye AO; Oni IO; Collier A
Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
5. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Fleming N; Hamblin PS; Story D; Ekinci EI
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
[TBL] [Abstract][Full Text] [Related]
6. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
Wei W; Liu J; Chen S; Xu X; Guo D; He Y; Huang Z; Wang B; Huang H; Li Q; Chen J; Chen H; Tan N; Liu Y
Front Endocrinol (Lausanne); 2022; 13():850836. PubMed ID: 35330914
[TBL] [Abstract][Full Text] [Related]
7. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
8. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
Taverner S; Eng C; Watson R; George S; Edwards A; Williams DM; Stephens JW
Diabetes Metab Syndr; 2022 Dec; 16(12):102658. PubMed ID: 36371968
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.
Lemke A; Brokmeier HM; Leung SB; Mara KC; Mour GK; Wadei HM; Hill JM; Stegall M; Kudva YC; Shah P; Kukla A
Clin Transplant; 2022 Aug; 36(8):e14718. PubMed ID: 35593882
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
12. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
13. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
[TBL] [Abstract][Full Text] [Related]
14. Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence.
Thiruvenkatarajan V; Inglis JM; Meyer E; Umapathysivam MM; Nanjappa N; Van Wijk R; Jesudason D
Can J Diabetes; 2023 Apr; 47(3):287-291. PubMed ID: 36739255
[TBL] [Abstract][Full Text] [Related]
15. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
16. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
19. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
20. Sodium glucose co-transporter-2 inhibitor-induced diabetic ketoacidosis following tooth extraction: improving awareness among dental practitioners.
Yap SD; Hamblin PS; Bach L; Ekinci E; Wong R
Aust Dent J; 2021 Dec; 66(4):444-447. PubMed ID: 34432892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
